mirikizumab
eli lilly
['lucent-1', ' uc ', 'mirikizumab']
 early symptom control with mirikizumab in uc patients (lucent-1 induction trial) - as of wk 2 sign improvments in stool frequency, rectal bleeding, urgency and fatigue under mirikizumab #uegweek22 
Professor of Medicine, Gastroenterologist, specializing in the care of patients with IBD.
National representative of Germany @ https://t.co/Qr0PthTmU8 ex @Y_ECCO_IBD chair